Jennifer Schofield

Senior research technician

School/Department: Leicester Drug Discovery and Diagnostics (LD3)



Jenny joined LD3 in April 2018, and worked on an in-vivo oncology project: Discovery Partnerships with Academia (DPAc) in collaboration with GlaxoSmithKline (GSK). Jenny has trained in Cat 3 work and has assisted on in-vivo projects with Mycobacterium tuberculosis (Mtb). More recently she has been involved with project managing and technical expertise for an in-vivo proof of concept using bacteriophages to treat antibiotic resistant Urinary Tract Infections (UTIs).


Andrew C. Pearce , Mark J. Bamford , Ruth Barber , Angela Bridges , Maire A. Convery , Constantinos Demetriou , Sian Evans , Thomas Gobbetti , David J. Hirst , Duncan S. Holmes , Jonathan P. Hutchinson , Sandrine Jayne , Larissa Lezina, Michael T. McCabe , Cassie Messenger , Joanne Morley , Melissa C. Musso, Paul Scott-Stevens , Ana Sousa Manso, Jennifer Schofield , Tom Slocombe , Don Somers , Ann L. Walker , Anastasia Wyce , Xi-Ping Zhang , and Simon D. Wagner.

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice. 

Received for publication, January 12, 2021 and in revised form, June 24, 2021 Published, Papers in Press, July 15, 2021, Read the article here


Sarah M.Glenn, Olbolbek Turapov, Vadim makarov, Douglas B.Kell, Galina Mukamolova.

Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis. Front cell infect Microbiol 2022; 12: 957287.

Published online 2022 Aug 24. doi: 10.3389/fcimb.2022.957287 Read the article here 

Back to top